Study Suggests Modern Drugs Reduce Risk of Heart Attacks
Posted on: Monday, 4 December 2006, 09:01 CST
New research suggests that modern combination drugs significantly reduce the risk of heart attacks as early as 90 days after the start of treatment.
The risk of heart attack can be reduced by more than 50% by combining a cholesterol-reducing drug, atorvastatin calcium, with a blood pressure-lowering drug amlodipine besylate, a calcium channel blocker.
Additionally the simultaneous initiation of atorvastatin and amlodipine treatment was about three times more effective at preventing heart attacks than adding atorvastatin, a statin, to one of the world's most widely used blood pressure-lowering drugs, atenolol, a beta-blocker.
According to a principal investigator, Professor Peter Sever of the International Centre for Circulatory Health, Imperial College, London, UK, these results have major implications for physicians and their patients worldwide.
The combination of amlodipine and atorvastatin demonstrates that the risk of heart attacks can be more than halved in the many patients at moderate risk who doctors see every day. In addition, there is a reduction in strokes of 25%.
"However, if we continue to use older blood pressure-lowering drugs, such as atenolol, and choose only to treat high blood pressure in isolation without giving a statin, we only confer a small part of this potential benefit. As a result, the risk of heart attacks and strokes remains unacceptably high in too many patients despite treatment to blood pressure targets," professor Sever said.
"It is vital that we use the right combination from the start to maximize the reduction in cardiac risk."
Source: Datamonitor
Related Articles
- Sleep Apnea May Cause Heart Disease In Kidney Transplant Patients
- Repligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
- Bad Neighborhoods Increase Risk Of High Blood Pressure
- C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients With Hereditary Angioedema, According to Pivotal Study
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- ACTOS(R) (Pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
- Heart Disease Blood Test May Predict Risk
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- Xolair (Omalizumab) Add-On Therapy Significantly Reduces Attacks in Patients With Severe Allergic Asthma
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds